Low-grade Gliomas in Children

References (42)

1. 1 IDH mutation in glioma: molecular mechanisms and potential therapeutic targets [DOI]
2. 2 Guidelines on management of low‐grade gliomas: report of an EFNS–EANO* Task Force [DOI]
3. 3 Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions [DOI]
4. 4 FDA Approval Summary: Dabrafenib in Combination with Trametinib for BRAFV600E Mutation–Positive Low-Grade Glioma [DOI]
5. 5 TP53 Mutation Is a Prognostic Factor in Lower Grade Glioma and May Influence Chemotherapy Efficacy [DOI]
6. 6 Resistance, rebound, and recurrence regrowth patterns in pediatric low-grade glioma treated by MAPK inhibition: A modified Delphi approach to build international consensus-based definitions—International Pediatric Low-Grade Glioma Coalition [DOI]
7. 7 Nidogen-1 expression is associated with overall survival and temozolomide sensitivity in low-grade glioma patients [DOI]
8. 8 Comprehensive analysis of MYB/MYBL1 -altered pediatric-type diffuse low-grade glioma [DOI]
9. 9 Advances in Immune Microenvironment and Immunotherapy of Isocitrate Dehydrogenase Mutated Glioma [DOI]
10. 10 Increased confidence of radiomics facilitating pretherapeutic differentiation of BRAF-altered pediatric low-grade glioma [DOI]
11. 11 Low-grade glioma in children with neurofibromatosis type 1: surveillance, treatment indications, management, and future directions [DOI]
12. 12 Radiomic features from multiparametric magnetic resonance imaging predict molecular subgroups of pediatric low-grade gliomas [DOI]
13. 13 Rebound growth of BRAF mutant pediatric glioma cells after MAPKi withdrawal is associated with MAPK reactivation and secretion of microglia-recruiting cytokines [DOI]
14. 14 Chemotherapy in pediatric low-grade gliomas (PLGG) [DOI]
15. 15 T2-FLAIR Mismatch: An Imaging Biomarker for Children’s MYB/MYBL1 –Altered Diffuse Astrocytoma or Angiocentric Glioma [DOI]
16. 16 Low-grade glioma of the temporal lobe and tumor-related epilepsy in children [DOI]
17. 17 Clinicopathological analysis of BRAF and non-BRAF MAPK pathway-altered gliomas in paediatric and adult patients: a single-institution study of 40 patients [DOI]
18. 18 Phase II study of vemurafenib in children and young adults with tumors harboring BRAF V600 mutations: NCI-COG pediatric MATCH trial (APEC1621) Arm G [DOI]
19. 19 Survivors of infant atypical teratoid/rhabdoid tumors present with severely impaired cognitive functions especially for fluid intelligence and visual processing: data from the German brain tumor studies [DOI]
20. 20 Optimizing preclinical pediatric low-grade glioma models for meaningful clinical translation [DOI]
21. 21 Considering Functional Outcomes as Efficacy Endpoints in Pediatric Low-Grade Glioma Clinical Trials: An FDA Educational Symposium [DOI]
22. 22 MOST wanted: navigating the MAPK-OIS-SASP-tumor microenvironment axis in primary pediatric low-grade glioma and preclinical models [DOI]
23. 23 Consensus framework for conducting phase I/II clinical trials for children, adolescents, and young adults with pediatric low-grade glioma: Guidelines established by the International Pediatric Low-Grade Glioma Coalition Clinical Trial Working Group [DOI]
24. 24 Improving long-term outcomes in pediatric low-grade glioma [DOI]
25. 25 Predicting histological grade in pediatric glioma using multiparametric radiomics and conventional MRI features [DOI]
26. 26 Challenges in treating children with optic pathway gliomas: an 18-year experience from a middle-income country [DOI]
27. 27 Transcriptomic Analysis of Glioma Based on IDH Status Identifies ACAA2 as a Prognostic Factor in Lower Grade Glioma [DOI]
28. 28 A paradigm shift in how we treat pediatric low-grade glioma—Targeting the molecular drivers [DOI]
29. 29 How will tovorafenib change our treatment of pediatric low-grade glioma? [DOI]
30. 30 Diffuse Gliomas with FGFR3::TACC3 Fusion: Morphological and Molecular Features and Classification Challenges [DOI]
31. 31 Prognostic utility and characteristics of MIB-1 labeling index as a proliferative activity marker in childhood low-grade glioma: a retrospective observational study [DOI]
32. 32 Radiotherapy for pediatric low-grade glioma [DOI]
33. 33 [11C]-methionine positron emission tomography in the evaluation of pediatric low-grade gliomas [DOI]
34. 34 Molecular-targeted therapy for childhood low-grade glial and glioneuronal tumors [DOI]
35. 35 Germline BRCA2 pathogenic variants in pediatric ganglioglioma: Case report and review of the literature [DOI]
36. 36 Concurrent EGFR amplification and TP53 mutation in glioblastomas [DOI]
37. 37 Dabrafenib plus Trametinib: A breakthrough in pediatric low‐grade glioma therapy [DOI]
38. 38 Targeted Therapy Win in BRAF-Mutant Gliomas [DOI]
39. 39 Brain stem tumors in children less than 3 months: Clinical and radiologic findings of a rare disease [DOI]
40. 40 Optic Pathway Gliomas: The Trends of Basic Research to Reduce the Impact of the Disease on Visual Function [DOI]
41. 41 The importance of escalating molecular diagnostics in patients with low-grade pediatric brain cancer [DOI]
42. 42 Author Correction: The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial [DOI]

Cited by 0

No indexed citations yet.

Related research

• Pattern of Hearing Impairment in a Tertiary Institution in Ado Ekiti, Nigeria — shares topic coverage
• Weight Gain as Tuberculosis Treatment Regimen Progresses in Patients Receiving Antituberculosis Therapy — shares topic coverage
• TREAT-B has Good Accuracy in Selecting HBV Infected Patients for Treatment in Sudan — shares topic coverage
• Botox Treatment: A Comprehensive Review — shares topic coverage
• Harnessing Artificial Intelligence in Healthcare Analytics: From Diagnosis to Treatment Optimization — shares topic coverage